Patent · US Expired

[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph

US7148231B2 · kind B2 · utility

2Cited by

0References

7Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Andre Bubendorf · Uffheim, FR
Michael Hennig · Weil am Rhein, DE
Pirmin Hidber · Basel, CH
Goesta Rimmler · Bad Krozingen, DE
Franziska E. Rohrer · Riehen, CH

Key dates

Filing date	Feb 3, 2004
Grant date	Dec 12, 2006
Priority date	—
Expiry date	Feb 27, 2024

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D239/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is concerned with a novel polymorph of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride. This polymorph exhibits superior properties compared to the previously known forms of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride. The [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride is an inhibitor of tyrosine kinase enzymes, and are useful in the treatment of cancer. Also disclosed are methods of making and using the novel polymorph, as well as pharmaceutical compositions containing the novel polymorph.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.